Plasma and red blood cell concentrations of amiodarone during chronic therapy

James J. Heger, Elizabeth B. Solow, Eric N. Prystowsky, Douglas P. Zipes

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Amiodarone and a metabolite, desethylamiodarone, were measured in plasma of 55 patients and in both plasma and red blood cell (RBC) in 28 patients who received chronic amiodarone treatment. The assay for amiodarone and desethylamiodarone was performed by high-pressure liquid chromatography. During chronic treatment, median plasma concentration of amiodarone was 2.80 μg/ml and desethylamiodarone was 2.20 μg/ml. In matched samples, plasma amiodarone concentration exceéded RBC amiodarone concentration (p <0.001) and the RBC-to-plasma concentration ratio averaged 0.31. The plasma desethylamiodarone concentration was not significantly different from its RBC concentration, and the RBC-to-plasma concentration ratio averaged 1.29. There was a linear correlation between plasma concentrations of amiodarone and desethylaminodarone (r = 0.82) and between RBC concentrations of drug and metabolite (r = 0.71). Drug or metabolite concentrations in plasma and RBCs correlated directly with daily dosage of amiodarone. Adverse side effects during chronic amiodarone therapy were related most strongly to RBC drug and metabolite concentrations. The group with adverse side effects had a significantly higher RBC concentration of amiodarone, 150 vs 0.75 μg/ml (p <0.001), than did patients free of adverse effects. After dosage reduction, side effects abated and plasma and RBC concentrations of drug and metabolite decreased. These data indicate that there is an expected range of amiodarone and desethylamiodarone concentrations during chronic treatment and that adverse side effects correlate best with RBC concentrations of drug and metabolite. Red cell concentrations may reflect the amount of unbound, free amiodarone and desethylamiodarone in plasma.

Original languageEnglish (US)
Pages (from-to)912-917
Number of pages6
JournalThe American journal of cardiology
Volume53
Issue number7
DOIs
StatePublished - Mar 15 1984

Fingerprint

Amiodarone
Erythrocytes
Therapeutics
Pharmaceutical Preparations
desethylamiodarone
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Plasma and red blood cell concentrations of amiodarone during chronic therapy. / Heger, James J.; Solow, Elizabeth B.; Prystowsky, Eric N.; Zipes, Douglas P.

In: The American journal of cardiology, Vol. 53, No. 7, 15.03.1984, p. 912-917.

Research output: Contribution to journalArticle

Heger, James J. ; Solow, Elizabeth B. ; Prystowsky, Eric N. ; Zipes, Douglas P. / Plasma and red blood cell concentrations of amiodarone during chronic therapy. In: The American journal of cardiology. 1984 ; Vol. 53, No. 7. pp. 912-917.
@article{da63c0c1ef8c48769f750f50f9c56d3a,
title = "Plasma and red blood cell concentrations of amiodarone during chronic therapy",
abstract = "Amiodarone and a metabolite, desethylamiodarone, were measured in plasma of 55 patients and in both plasma and red blood cell (RBC) in 28 patients who received chronic amiodarone treatment. The assay for amiodarone and desethylamiodarone was performed by high-pressure liquid chromatography. During chronic treatment, median plasma concentration of amiodarone was 2.80 μg/ml and desethylamiodarone was 2.20 μg/ml. In matched samples, plasma amiodarone concentration exce{\'e}ded RBC amiodarone concentration (p <0.001) and the RBC-to-plasma concentration ratio averaged 0.31. The plasma desethylamiodarone concentration was not significantly different from its RBC concentration, and the RBC-to-plasma concentration ratio averaged 1.29. There was a linear correlation between plasma concentrations of amiodarone and desethylaminodarone (r = 0.82) and between RBC concentrations of drug and metabolite (r = 0.71). Drug or metabolite concentrations in plasma and RBCs correlated directly with daily dosage of amiodarone. Adverse side effects during chronic amiodarone therapy were related most strongly to RBC drug and metabolite concentrations. The group with adverse side effects had a significantly higher RBC concentration of amiodarone, 150 vs 0.75 μg/ml (p <0.001), than did patients free of adverse effects. After dosage reduction, side effects abated and plasma and RBC concentrations of drug and metabolite decreased. These data indicate that there is an expected range of amiodarone and desethylamiodarone concentrations during chronic treatment and that adverse side effects correlate best with RBC concentrations of drug and metabolite. Red cell concentrations may reflect the amount of unbound, free amiodarone and desethylamiodarone in plasma.",
author = "Heger, {James J.} and Solow, {Elizabeth B.} and Prystowsky, {Eric N.} and Zipes, {Douglas P.}",
year = "1984",
month = "3",
day = "15",
doi = "10.1016/0002-9149(84)90524-1",
language = "English (US)",
volume = "53",
pages = "912--917",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Plasma and red blood cell concentrations of amiodarone during chronic therapy

AU - Heger, James J.

AU - Solow, Elizabeth B.

AU - Prystowsky, Eric N.

AU - Zipes, Douglas P.

PY - 1984/3/15

Y1 - 1984/3/15

N2 - Amiodarone and a metabolite, desethylamiodarone, were measured in plasma of 55 patients and in both plasma and red blood cell (RBC) in 28 patients who received chronic amiodarone treatment. The assay for amiodarone and desethylamiodarone was performed by high-pressure liquid chromatography. During chronic treatment, median plasma concentration of amiodarone was 2.80 μg/ml and desethylamiodarone was 2.20 μg/ml. In matched samples, plasma amiodarone concentration exceéded RBC amiodarone concentration (p <0.001) and the RBC-to-plasma concentration ratio averaged 0.31. The plasma desethylamiodarone concentration was not significantly different from its RBC concentration, and the RBC-to-plasma concentration ratio averaged 1.29. There was a linear correlation between plasma concentrations of amiodarone and desethylaminodarone (r = 0.82) and between RBC concentrations of drug and metabolite (r = 0.71). Drug or metabolite concentrations in plasma and RBCs correlated directly with daily dosage of amiodarone. Adverse side effects during chronic amiodarone therapy were related most strongly to RBC drug and metabolite concentrations. The group with adverse side effects had a significantly higher RBC concentration of amiodarone, 150 vs 0.75 μg/ml (p <0.001), than did patients free of adverse effects. After dosage reduction, side effects abated and plasma and RBC concentrations of drug and metabolite decreased. These data indicate that there is an expected range of amiodarone and desethylamiodarone concentrations during chronic treatment and that adverse side effects correlate best with RBC concentrations of drug and metabolite. Red cell concentrations may reflect the amount of unbound, free amiodarone and desethylamiodarone in plasma.

AB - Amiodarone and a metabolite, desethylamiodarone, were measured in plasma of 55 patients and in both plasma and red blood cell (RBC) in 28 patients who received chronic amiodarone treatment. The assay for amiodarone and desethylamiodarone was performed by high-pressure liquid chromatography. During chronic treatment, median plasma concentration of amiodarone was 2.80 μg/ml and desethylamiodarone was 2.20 μg/ml. In matched samples, plasma amiodarone concentration exceéded RBC amiodarone concentration (p <0.001) and the RBC-to-plasma concentration ratio averaged 0.31. The plasma desethylamiodarone concentration was not significantly different from its RBC concentration, and the RBC-to-plasma concentration ratio averaged 1.29. There was a linear correlation between plasma concentrations of amiodarone and desethylaminodarone (r = 0.82) and between RBC concentrations of drug and metabolite (r = 0.71). Drug or metabolite concentrations in plasma and RBCs correlated directly with daily dosage of amiodarone. Adverse side effects during chronic amiodarone therapy were related most strongly to RBC drug and metabolite concentrations. The group with adverse side effects had a significantly higher RBC concentration of amiodarone, 150 vs 0.75 μg/ml (p <0.001), than did patients free of adverse effects. After dosage reduction, side effects abated and plasma and RBC concentrations of drug and metabolite decreased. These data indicate that there is an expected range of amiodarone and desethylamiodarone concentrations during chronic treatment and that adverse side effects correlate best with RBC concentrations of drug and metabolite. Red cell concentrations may reflect the amount of unbound, free amiodarone and desethylamiodarone in plasma.

UR - http://www.scopus.com/inward/record.url?scp=0021365457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021365457&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(84)90524-1

DO - 10.1016/0002-9149(84)90524-1

M3 - Article

C2 - 6538381

AN - SCOPUS:0021365457

VL - 53

SP - 912

EP - 917

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -